Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Chinese Patent Office
Cipla
QuintilesIMS
Julphar
Colorcon
McKesson
Queensland Health
Baxter
Johnson and Johnson

Generated: October 20, 2017

DrugPatentWatch Database Preview

ELOXATIN Drug Profile

« Back to Dashboard

What is the patent landscape for Eloxatin, and when can generic versions of Eloxatin launch?

Eloxatin is a drug marketed by Sanofi Aventis Us and is included in two NDAs. There is one patent protecting this drug and four Paragraph IV challenges.

This drug has five patent family members in four countries.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

Summary for Tradename: ELOXATIN

US Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Clinical Trials: see list79
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ELOXATIN at DailyMed

Pharmacology for Tradename: ELOXATIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005APRXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-001Aug 9, 2002DISCNYesNo► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-002Jan 31, 2005APRXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-003Nov 17, 2006DISCNYesNo► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-002Aug 9, 2002DISCNYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ELOXATIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-002Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-002Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-001Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-001Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-002Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-001Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021492-002Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ELOXATIN

Drugname Dosage Strength RLD Submissiondate
oxaliplatinInjection5 mg/mL, 40 mL vialEloxatin3/23/2011
oxaliplatinInjection200 mg/40 mLEloxatin7/16/2007
oxaliplatinInjection5 mg/mL, 10 mL and 20 mL vialsEloxatin2/9/2007
oxaliplatinFor Injection50 mg/vial and 100 mg/vialEloxatin2/9/2007

International Patent Family for Tradename: ELOXATIN

Country Document Number Estimated Expiration
Japan3025602► Subscribe
European Patent Office0625523► Subscribe
Spain2167328► Subscribe
Germany69331048► Subscribe
JapanH06329692► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
UBS
Novartis
Citi
Mallinckrodt
Chubb
AstraZeneca
Queensland Health
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot